Eloxx Pharmaceuticals, Inc.
(NASDAQ : ELOX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.46%74.100.0%$2395.49m
NVAXNovavax, Inc. 1.67%170.2999.2%$1218.87m
SRNESorrento Therapeutics, Inc. 5.95%14.421.8%$598.67m
GILDGilead Sciences, Inc. 0.79%69.351.0%$559.14m
AMGNAmgen, Inc. -0.36%240.691.3%$476.61m
REGNRegeneron Pharmaceuticals, Inc. -0.16%620.212.5%$429.51m
BNTXBioNTech SE -0.10%77.000.0%$399.56m
VRTXVertex Pharmaceuticals, Inc. -0.13%272.991.9%$368.45m
BIIBBiogen, Inc. 10.10%305.711.6%$361.06m
ILMNIllumina, Inc. -10.94%355.663.5%$336.82m
VXRTVaxart, Inc. 1.05%9.190.0%$280.99m
EBSEmergent BioSolutions, Inc. 2.91%130.666.4%$180.62m
ALXNAlexion Pharmaceuticals, Inc. -0.60%103.282.0%$166.60m
SGENSeattle Genetics, Inc. -0.83%160.456.0%$163.01m
IBIOiBio, Inc. -6.65%3.790.2%$158.51m

Company Profile

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Waltham, MA.